A Review on the Relationship between SGLT2 Inhibitors and Cancer
Table 1
SGLT2 inhibitors under phase II and phase III clinical trials.
Drug
Company
Phase of clinical trial
Dapagliflozin (BMS-512148)
Bristol-Myers Squibb/AstraZeneca
Phase III (approved in Australia (Oct 2012), Europe (Nov 2012), Mexico (Mar 2013), New Zealand (June 2013), Brazil (July 2013), Argentina (Sep 2013), US (Jan 2014), and Japan (Mar 2014))
Canagliflozin (TA-7284, JAJ-28431754)
Johnson and Johnson and Mitsubishi Tanabe Pharma
Phase III (approved in US (Mar 2013) and Europe (Nov 2013))
Empagliflozin (BI-10773)
Boehringer Ingelheim/Lilly
Phase III (approved in Europe (May 2014))
Ipragliflozin (ASP-1941)
Astellas Pharma and Kotobuki Pharmaceutical Company
